We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cystamine slows but not inverses the progression of monocrotaline-induced pulmonary arterial hypertension in rats.
- Authors
Wang, Han-Ming; Liu, Wan-Zhu; Tang, Fu-Tian; Sui, Hai-Juan; Zhan, Xing-Jie; Wang, Hong-Xin
- Abstract
Tissue transglutaminase (TG2) plays an important role in pulmonary arterial hypertension (PAH). Previous research indicate that TG2 and protein serotonylation catalyzed by TG2 are upregulated in PAH. Serotonin transporter inhibitor fluoxetine ameliorates PAH via inhibition of protein serotonylation. It is still unknown whether PAH is inhibited through direct inhibition of TG2. Therefore, the present study aimed to investigate the effects of TG2 inhibitor cystamine on monocrotaline-induced PAH in rats. Rats were treated with monocrotaline (60 mg·kg−1, i.p.) in combination with or without cystamine (20, 40 mg·kg−1·day−1, p.o.). The results showed that compared with monocrotaline alone, combination of monocrotaline with cystamine (40 mg·kg−1·day−1, p.o.) relieved right ventricle hypertrophy, inhibited pulmonary arteriolar remodeling, and downregulated protein expression of TG2, phosphorylated protein kinase B (Akt), and extracellular regulated protein kinase (ERK) at day 21. However, except for TG2 expression, these changes were not significantly inhibited by cystamine at day 35. In addition, cystamine dose-dependently enhanced the survival rate of rats injected with monocrotaline at day 35. The findings suggest that cystamine slows but not reverses monocrotaline-induced PAH in rats, which was largely associated with the inhibition of TG2 protein expression and Akt and ERK activation.
- Subjects
CYSTAMINE; MONOCROTALINE; PULMONARY hypertension prevention; PULMONARY circulation; LABORATORY mice
- Publication
Canadian Journal of Physiology & Pharmacology, 2018, Vol 96, Issue 8, p783
- ISSN
0008-4212
- Publication type
Article
- DOI
10.1139/cjpp-2017-0720